scholarly journals Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Naoto Tokuda ◽  
Yasushi Kitaoka ◽  
Akiko Matsuzawa ◽  
Ayaka Tsukamoto ◽  
Kana Sase ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Barrier Function ◽  
Benzalkonium Chloride ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Surface Characteristics ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial ◽  
Preservative Free

Purpose. The aim of the present study was to examine the effects of switching from Latanoprost ophthalmic solution containing a preservative to preservative-free Tafluprost ophthalmic solution or Tafluprost containing a preservative on ocular surfaces. Materials and Methods. Forty patients (40 eyes) with glaucoma (mean age: 62.0 ± 10.9 years) using Latanoprost with preservative for six months or longer were assigned either to a Tafluprost-containing-preservative group (20 eyes) or preservative-free-Tafluprost group (20 eyes). The intraocular pressure, corneal epithelial barrier function (fluorescein uptake concentration with fluorophotometer FL-500), superficial punctate keratopathy (AD classification), and tear film breakup time (TBUT) were assessed before switching and at 12 weeks after switching. Results. No significant differences in intraocular pressure were noted after switching in either group. Corneal epithelial barrier function was improved significantly after switching in both the Tafluprost-containing-preservative and the preservative-free-Tafluprost groups. There were no significant differences in AD scores after switching in the Tafluprost-containing-preservative group, but significant improvements were noted in the preservative-free-Tafluprost group. No significant differences in TBUT were noted in the Tafluprost-containing-preservative or preservative-free-Tafluprost groups after switching. Conclusion. After switching from preservative Latanoprost to Tafluprost containing-preservative or preservative-free Tafluprost, corneal epithelial barrier function was improved while the intraocular pressure reduction was retained.

scholarly journals The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Naoto Tokuda ◽  
Yasushi Kitaoka ◽  
Akiko Matsuzawa ◽  
Junsuke Miyamoto ◽  
Shinsuke Sakae ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ocular Surface ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Control Group ◽  
Eye Drops ◽  
Drug Induced ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial ◽  
Significant Difference

Purpose. To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma eye drops.Patients and Methods. Forty eyes of 40 patients receiving latanoprost (0.005%) and timolol (0.5%) were included in this randomized prospective study. The patients were randomly divided into two groups (n= 20): the rebamipide-treated group and control group. Changes in intraocular pressure, tear film break-up time (TBUT), and corneal epithelial barrier function were evaluated at baseline, 4 weeks, and 8 weeks after rebamipide administration. Furthermore, superficial punctate keratopathy severity was evaluated by scoring the lesion area and density.Results. There was no significant difference in intraocular pressure before and after rebamipide treatment. However, corneal epithelial barrier function improved significantly 4 and 8 weeks after rebamipide treatment. TBUT was partially, but significantly, increased (P= 0.02) 8 weeks after rebamipide treatment, whereas no significant change was observed at 4 weeks. Additionally, a significant decrease in area and density of keratopathy was observed 8 weeks after rebamipide treatment but not at 4 weeks. The control group showed no significant difference compared to baseline.Conclusions. Our data suggests that rebamipide treatment may reduce the occurrence of drug-induced ocular surface disorder.

scholarly journals The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension

2018 ◽  
Vol 29 (2) ◽  
pp. 210-215 ◽  
Author(s):  
Marta Misiuk-Hojlo ◽  
Maria Pomorska ◽  
Malgorzata Mulak ◽  
Marek Rekas ◽  
Joanna Wierzbowska ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Intraocular Pressure ◽  
Standard Deviation ◽  
Ocular Hypertension ◽  
Benzalkonium Chloride ◽  
Tear Film ◽  
Corrected Visual Acuity ◽  
Break Up ◽  
Preservative Free ◽  
Best Corrected Visual Acuity

Purpose: To assess tolerability and efficacy following a switch from benzalkonium chloride–latanoprost to preservative-free latanoprost in patients with glaucoma or ocular hypertension. Methods: A total of 140 patients with glaucoma or ocular hypertension controlled with benzalkonium chloride-latanoprost for at least 3 months were switched to treatment with preservative-free latanoprost. Assessments were made on days 15, 45, and 90 (D15, D45, and D90) and included best-corrected visual acuity, intraocular pressure, slit lamp examination, fluorescein staining, tear film break-up time, patient symptom evaluation, and subjective estimation of tolerability. Results: Mean best-corrected visual acuity remained unchanged during the study. Mean intraocular pressure compared with baseline (D0) remained stable throughout the study (D0, 15.9 mmHg (standard deviation = 2.6); D90, 15.3 mmHg (standard deviation = 2.4); p < 0.006). Tear film break-up time improved or remained unchanged relative to baseline in 92% of patients at D45 and in 93% at D90. Moderate-to-severe conjunctival hyperemia was seen in 56.8% of patients at D0, but this figure decreased to 13.7%, 2.2%, and 1.6% at D15, D45, and D90, respectively. Subjective assessment of tolerability (0–10 scale) indicated improvement with change of therapy (mean score: 5.3 (standard deviation = 2.2) at D0 versus 1.9 (standard deviation = 1.7) at D90; p < 0.0001). Conclusion: Preservative-free latanoprost has at least the same intraocular pressure-lowering efficacy as benzalkonium chloride–latanoprost, with a better tolerability profile. This may translate into greater control of treatment and improved quality of life.

Effect of Beta-Blocker Eyedrops on Corneal Epithelial Barrier Function

2000 ◽  
Vol 214 (5) ◽  
pp. 332-336 ◽  
Author(s):  
Akiko Niiya ◽  
Norihiko Yokoi ◽  
Yasuhiro Matsumoto ◽  
Aoi Komuro ◽  
Takeshi Ishibashi ◽  
...  
Keyword(s):  
Beta Blocker ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial

scholarly journals P 154 Effects of contact lens use to corneal epithelial barrier function by objective fluorophotometer

1995 ◽  
Vol 35 ◽  
pp. S180
Author(s):  
T. Takahashi ◽  
Y. Enomoto ◽  
M. Itoi ◽  
N. Itoh ◽  
K. Nakayasu ◽  
...  
Keyword(s):  
Contact Lens ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial

Impairment of corneal epithelial barrier function in diabetics

1989 ◽  
Vol 227 (2) ◽  
pp. 142-144 ◽  
Author(s):  
Martin Göbbels ◽  
Manfred Spitznas ◽  
Joachim Oldendoerp
Keyword(s):  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial
Sign in / Sign up

Export Citation Format

Share Document